Biogen Secures Global Rights to Felzartamab, Paying $100M Upfront for China Assets
BIIB sits 56% above its 52-week low of $114.66.
Summary
Biogen has entered into a definitive agreement to acquire exclusive rights to felzartamab in the Greater China Region from TJ Biopharma. This transaction, which includes a $100 million upfront payment and up to $750 million in potential milestone payments and royalties, grants Biogen worldwide rights to the late-stage asset. This deal significantly expands Biogen's commercial opportunity for felzartamab, a potential 'pipeline-in-a-product' currently in global Phase 3 studies for multiple immune-mediated diseases, including a Biologics License Application already under review in China for multiple myeloma. The upfront payment will be recorded as an Acquired In-Process Research and Development expense in Q2 2026. Traders will monitor the progress of felzartamab's clinical trials and regulatory reviews, particularly in the large Greater China market.
At the time of this announcement, BIIB was trading at $179.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26B. The 52-week trading range was $114.66 to $202.41. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.